Event

Dr. Zoubeidi’s research program aims to provide mechanistic insight into the molecular (genetic and epigenetic) sources that fuel tumor cell plasticity and emergent resistance phenotypes following targeted therapy. In this seminar, Dr. Zoubeidi will discuss lineage plasticity in treatment resistance prostate cancer. She will discuss how she leverages this information and this knowledge to identify early detection biomarkers and nominate new targets to block the mechanisms utilized by tumor cells to gain access to cell plasticity that can be used alone or in combination to improve the efficacy of existing therapies and patient outcomes. Importantly, as lineage reprogramming is emerging as a conserved mechanism of resistance across tumor types, results from this program may have relevance in other highly prevalent cancers, such as melanoma and lung and breast cancer.